PET-CT for Liver Cancer — Why It Often Misses HCC

Yes, and this is especially common with HCC. Well-differentiated tumour cells retain an enzyme that prevents the radioactive tracer from building up, so a PET scan can come back negative even when a tumour is present and active. This is why AASLD and EASL guidelines do not recommend PET-CT as a standard test for diagnosing or staging HCC. Your team uses multiphasic CT or MRI instead, which detects HCC through its blood-flow pattern rather than its glucose metabolism.

Multiphasic CT and MRI with contrast are the standard imaging for HCC according to AASLD and EASL guidance. Both detect the characteristic way HCC brightens in the arterial phase and washes out later — a pattern that allows confident identification in most cases. Liver-specific MRI contrast agents such as gadoxetate can improve sensitivity for smaller lesions. Which is recommended for you depends on your kidney function, any implants, and the specific question your team needs to answer.

Because CT and MRI are more reliable for HCC than PET. HCC has a distinctive appearance on contrast-enhanced CT and MRI — it brightens when arterial blood first arrives, then washes out in later phases — that allows confident identification in most cases without a biopsy. PET works by detecting high glucose uptake, but most HCC cells do not consume glucose the way most other cancers do, which makes PET an unreliable primary tool for this disease.

Through a combination of surveillance, contrast imaging and blood tests. People at risk — typically those with cirrhosis or chronic hepatitis — are recommended by AASLD to have ultrasound every six months. If something is found, multiphasic CT or MRI is done to characterise it. An AFP blood test adds supporting information. In most cases these tools are enough to diagnose HCC without a biopsy, and PET is not part of the standard detection pathway.

LI-RADS 5 means the radiologist is confident the finding is HCC, based on its typical pattern on CT or MRI — arterial enhancement followed by washout. It is the highest category on the LI-RADS scale. It is a radiological assessment, not a final diagnosis; your oncologist will discuss what it means for your treatment plan. A score of LR-5 in someone with cirrhosis or another liver disease risk factor is taken seriously and typically leads to prompt discussion of treatment options.

Yes, in selected situations. PET may be ordered when the cancer is high-grade or poorly differentiated, as these tumours are more likely to absorb the tracer. It is also used when the team wants to check for spread to lymph nodes, bone or lung, or before a liver transplant assessment. If your doctor has ordered a PET-CT, ask what specific question it is being used to answer — understanding that will help you make sense of the result when it comes back.